Lipid Based nanoformulation of lycopene improves oral delivery: formulation optimization, ex vivo assessment and its efficacy against breast cancer

Journal of Microencapsulation

Volumn 34, Issue 4, 2017, Pages 416-429

  Singh, Archu ^a   Neupane, Yub Raj ^a   Panda, Bibhu Prasad ^b   Kohli, Kanchan ^a  

^a HAMDARD UNIVERSITY   (India)

^b Jamia Hamdard   (India)

Author keywords

antioxidant assay; box Behnken design; Lycopene; MTT assay; NLC; precirol ATO 5; stability studies

Indexed keywords

LIPID; LYCOPENE; NANOCARRIER; CAROTENOID; DRUG CARRIER; EXCIPIENT;

ABTS RADICAL SCAVENGING ASSAY; ANIMAL TISSUE; ARTICLE; BREAST CANCER; CONTROLLED STUDY; DISPERSITY; DPPH RADICAL SCAVENGING ASSAY; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG CYTOTOXICITY; DRUG DELIVERY SYSTEM; DRUG EFFICACY; DRUG FORMULATION; DRUG PENETRATION; EX VIVO STUDY; HUMAN; HUMAN CELL; IC50; MALE; MTT ASSAY; NANOENCAPSULATION; NONHUMAN; PARTICLE SIZE; RAT; SUSTAINED DRUG RELEASE; ZETA POTENTIAL; ANIMAL; BREAST TUMOR; CHEMISTRY; DRUG RELEASE; MEDICINAL CHEMISTRY; ORAL DRUG ADMINISTRATION; TOMATO; TUMOR CELL LINE;

ADMINISTRATION, ORAL; ANIMALS; BREAST NEOPLASMS; CAROTENOIDS; CELL LINE, TUMOR; CHEMISTRY, PHARMACEUTICAL; DRUG CARRIERS; DRUG LIBERATION; EXCIPIENTS; HUMANS; LIPIDS; LYCOPERSICON ESCULENTUM; MALE; PARTICLE SIZE; RATS;

EID: 85021296623     PISSN: 02652048     EISSN: 14645246     Source Type: Journal    
DOI: 10.1080/02652048.2017.1340355     Document Type: Article

References (47)

1. Aghel N, Ramezani Z, Amirfakhrian S., Isolation and quantification of lycopene from tomato cultivated in Dezfoul, Iran. Jundishapur J Nat Pharm Prod, 2011;6(1):9–15.
2. Anton N, Benoit JP, Saulnier P. Design and production of nanoparticles formulated from nano-emulsion templates-a review. J Control Release, 2008;128(3):185–99.
3. Ascenso A, So´nia Pinho S, Carla Eleute´rio C, Fabíola Garcia Prac¸a FC, Bentley MVLB, Oliveira H, Santos C, Silva O, Simoes S., Lycopene from tomatoes:vesicular nanocarrier formulations for dermal delivery. J Agric Food Chem, 2013;61:7284–93.
4. Aune D, Chan DS, Vieira AR, Rosenblatt DA, Vieira R, Greenwood DC, Norat T., Fruits, vegetables and breast cancer risk:a systematic review and meta-analysis of prospective studies. Breast Cancer Res Treat, 2012;134:479–93.
5. Boileau TW, Boileau AC, Erdman JW. Bioavailability of all-trans and cis-isomers of lycopene. Exp Biol Med (Maywood), 2002;227:914–19.
6. Chaudhary H, Kohli K, Amin S, Rathee P, Kumar V., Optimization and formulation design of gels of diclofenac and curcumin for transdermal drug delivery by Box–Behnken statistical design. J Pharm Sci, 2010;100:580–93.
7. Chasse GA, Mak ML, Deretey E, Farkas I, Torday LL, Papp JG, Sarma DS, Agarwal A, Chakravarthi S, Agarwal S, Rao AV., An ab initio computational study on selected lycopene isomers. J Mol Struc (Theochem), 2001;571(1):27–37.
8. Chopra S, Patil GV, Motwani SK., Release modulating hydrophilic matrix systems of losartan potassium:optimization of formulation using statistical experimental design. Eur J Pharm Biopharm, 2007;66:73–82.
9. Das S, Ng WK, Kanaujia P, Kim S, Tan RHB., Formulation design, preparation and physicochemical characterizations of solid lipid nanoparticles containing a hydrophobic drug:effects of process variables. Colloids Surf B Biointerfaces, 2011;88:483–9.
10. Dash S, Murthy PN, Nath L, Chowdhary P. Kinetic modeling on drug release from controlled drug delivery systems. Acta Pol Pharm, 2010;67:217–23.
11. Faisal W, O’Driscoll CM, Griffin BT., Bioavailability of lycopene in the rat:the role of intestinal lymphatic transport. J Pharm Pharmacol, 2010;62:323–31.
12. Freitas C, Müller RH., Correlation between long-term stability of solid lipid nanoparticles (SLN) and crystallinity of the lipid phase. Eur J Pharm Biopharm, 1999;47:125–32.
13. Gannu R, Yamsani VV, Yamsani SK, Palem CR, Yamsani MR. Optimization of hydrogels for transdermal delivery of lisinopril by Box–Behnken statistical design. AAPS PharmSciTech, 2009;10:505–14.
14. Gartner C, Stahl W, Sies H., Lycopene is more bioavailable from tomato paste than from fresh tomatoes. Am J Clin Nutr, 1997;66:116–22.
15. Gutierrez JM, Gonzalez C, Maestro A, Sole I, Pey CM, Nolla J., Nanoemulsions:new applications and optimization of their preparation. Curr Opin Colloid Interf Sci, 2008;13(4):245–51.
16. Hatziantoniou S, Deli G, Nikas Y, Demetios C, Papaiannou GT., Scanning electron microscopy study on nanoemulsions and solid lipid nanoparticles containing high amount of ceramides. Micron, 2007;38:819–23.
17. How CW, Abdullah R, Abbasalipourkabir R., Physicochemical properties of nanostructured lipid carriers as colloidal carrier system stabilized with polysorbate 20 and polysorbate 80. Afr J Biotechnol, 2011;10(9):1684–9.
18. Huang Q, Yu H, Ru Q., Bioavailability and delivery of nutraceutical using nanotechnology. Concise reviews and hypotheses in. Food Sci, 2010;75(1):50–7.
19. Jenning V, Thunemann AF, Gohla SH., Characterization of a novel solid lipid nanoparticle carrier system based on binary mixtures of liquid and solid lipids. Int J Pharm, 2000;199:167–77.
20. Jenning V, Gohla SH., Encapsulation of retinoids in solid lipid nanoparticles (SLN). J Microencapsul, 2001;18(2):149–58.
21. Kasongo KW, Muller RH, Walker RB., The use of hot and cold high pressure homogenization to enhance the loading capacity and encapsulation efficiency of nanostructured lipid carriers for the hydrophilic antiretroviral drug, didanosine for potential administration to paediatric patients. Pharm Dev Technol, 2012;17(3):353–62.
22. Kumbhar DD, Pokharkar VB., Engineering of a nanostructured lipid carrier for the poorly water-soluble drug, bicalutamide:physicochemical investigations. Colloids Surf A Physicochem Eng Aspects, 2013;416:32–42.
23. Leo E, Cameroni R, Forni F., Dynamic dialysis for the drug release evaluation from doxorubicin–gelatin nanoparticle conjugates. Int J Pharm, 1999;180:23–30.
24. Leuner C, Dressman J., Improving drug solubility for oral delivery using solid dispersions. Eur J Pharm Biopharm, 2000;50:47–60.
25. Li HB, Wong CC, Cheng KW, Chen F., Antioxidant properties in vitro and total phenolic contents in methanol extracts from medicinal plants. Lwt, 2008;41:385–90.
26. Liu J, Hu W, Chen H, Ni Q, Xu H, Yang X., Isotretinoin-loaded solid lipid nanoparticles with skin targeting for topical delivery. Int J Pharm, 2007;328(2):191–5.
27. Mehnert W, Mader K., Solid lipid nanoparticles:production, characterization and applications. Adv Drug Deliv Rev, 2001;47:165–96.
28. Miller NJ, Sampson J, Candeias LP, Bramley PM, Rice-Evans CA., Antioxidant activities of carotenes and xanthophylls. FEBS Lett, 1996;384(3):240–2.
29. Muller RH, Runge S, Ravelli V, Mehnert W, Thunemann AF, Souto EB., Oral bioavailability of cyclosporine:solid lipid nanoparticles (SLNR) versus drug nanocrystals. Int J Pharm, 2006;317:82–9.
30. Negi LM, Jaggi M, Talegaonkar S., Development of protocol for screening the formulation components and the assessment of common quality problems of nano-structured lipid carriers. Int J Pharm, 2014;461:403–10.
31. Neupane YR, Sabir MD, Ahmad N, Ali M, Kohli K., Lipid drug conjugate nanoparticle as a novel lipid nanocarrier for the oral delivery of decitabine:ex vivo gut permeation studies. Nanotechnology, 2013;24:415102.
32. Nunes IL, Mercadante AZ., Encapsulation of lycopene using spray-drying and molecular inclusion processes. Brazilian Arch Biol Technol, 2007;50:893–900.
33. Porter CJH, Trevaskis NL, Charman WN., Lipids and lipid-based formulations:optimizing the oral delivery of lipophilic drugs. Nat Rev Drug Discov, 2007;6:231–48.
34. Rane SS, Anderson BD., What determines drug solubility in lipid vehicles:is it predictable? Adv Drug Deliv Rev, 2008;60:638–56.
35. Ribayo-Mercado JD, Garmyn M, Gilchrest BA, Russell RM., Skin lycopene is destroyed preferentially over beta carotene during ultraviolet irradiation in humans. J Nutr, 1995;125:1854–9.
36. Sánchez-Moreno C, Larrauri JA, Saura-Calixto F., A procedure to measure the antiradical efficiency of polyphenols. J Sci Food Agr, 1998;76(2):270–6.
37. Sathish T, Udayakiran D, Himabindu K., HPLC method for determination of lycopene in crude oleoresin extracts. Asian J Chem, 2009;21(1):139–48.
38. Schubert MA, Muller-Goymann CC., Solvent injection as a new approach for manufacturing lipid nanoparticles-evaluation of the method and process parameters. Eur J Pharm Biopharm, 2003;55:125–31.
39. Schwarz C, Mehnert W. Solid lipid nanoparticles (SLN) for controlled drug delivery. II. Drug incorporation and physicochemical characterization. J Microencapsul, 1999;16:205–13.
40. Souto EB, Wissing SA, Barbosa CM, Muller RH., Development of a controlled release formulation based on SLN and NLC for topical clotrimazole delivery. Int J Pharm, 2004;278:71–7.
41. Stahl W, Sies H., Lycopene:a biologically important carotenoid for humans? Arch Biochem Biophys, 1996;336:1–9.
42. Steven K, Clinton MD., Lycopene:chemistry, biology and implications for human health and disease. Nutr Rev, 1998;56:35–51.
43. Takeshima M, Ono M, Higuchi T, Chen C, Hara T, Nakano S., Anti-proliferative and apoptosis-inducing activity of lycopene against three subtypes of human breast cancer cell lines. Cancer Sci, 2014;105:252–7.
44. Vertzoni M, Valsami G, Reppas C., Plasma profiles of lycopene after single oral and intravenous administrations in dogs. J Pharm Pharmacol, 2006;58:1211–17.
45. Wei MY, Giovannucci EL., Lycopene, tomato products, and prostate cancer incidence:a review and reassessment in the PSA screening era. J Oncol, 2012;2012:271063.
46. Yang CR, Zhao X, Hu H, Li K, Sun X., Preparation, optimization and characteristic of huperzine A loaded nanostructured lipid carriers. Chem Pharm Bull, 2010;58(5):656–61.
47. Zhang J, Fan Y, Smith E., Experimental design for the optimization of lipid nanoparticles. J Pharm Sci, 2009;98(5):1813–19.